TALLYHO/JngJ response to rosiglitazone

JAX® In Vivo Pharmacology Services examined the ability of the reference compound, rosiglitazone, to lower blood glucose and improve glucose tolerance. TALLYHO/JngJ males at 9 weeks of age (n = 8) were dosed orally with 0, 3, or 30 mg/kg/day for 4 weeks. Fed blood glucose levels were recorded weekly and an oral glucose tolerance test (OGTT) was performed at study termination.

Change in fed blood glucose over time

Figure 1. Rosiglitazone at 3mg/kg had no effect, but 30mg/kg progressively lowered fed blood glucose.

Effect of rosiglitazone on glucose tolerance in fasting TALLYHO mice

Figure 2. Rosiglitazone at 30 mg/kg also improved the ability of TALLYHO/JngJ mice to clear blood glucose following challenge in the OGTT, indicating improved glucose tolerance.